You are here
Clinical Trials: Cord Blood
Conditions: MDS; Anemia, Aplastic; Inborn Errors of Metabolism; Congenital Marrow Failure; Congenital Immunodeficiency Syndrome
Intervention: Biological: ALDHbr Umbilical Cord Blood Cells
Sponsors: Joanne Kurtzberg, MD; Aldagen
Completed - verified April 2017
Intervention: Biological: ALDHbr Umbilical Cord Blood Cells
Sponsors: Joanne Kurtzberg, MD; Aldagen
Completed - verified April 2017
Conditions: Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: Fludarabine; Drug: mycophenolate mofetil; Radiation: total marrow irradiation; Procedure: umbilical cord blood transplantation; Biological: Granulocyte colony-stimulating factor; Biological: HLA-matched related donor bone marrow
Sponsor: Masonic Cancer Center, University of Minnesota
Completed - verified July 2017
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: Fludarabine; Drug: mycophenolate mofetil; Radiation: total marrow irradiation; Procedure: umbilical cord blood transplantation; Biological: Granulocyte colony-stimulating factor; Biological: HLA-matched related donor bone marrow
Sponsor: Masonic Cancer Center, University of Minnesota
Completed - verified July 2017
Conditions: Hurler's Syndrome; Maroteaux-Lamy Syndrome; Sly Syndrome; Alpha Mannosidosis; Fucosidosis; Aspartylglucosaminuria; Sphingolipidoses; Krabbe Disease; Wolman's Disease; Niemann-Pick Disease Type B; Niemann-Pick Disease, Type C
Interventions: Procedure: Stem Cell Transplantation; Drug: Cyclophosphamide; Drug: Campath-1H; Drug: Busulfan
Sponsor: Masonic Cancer Center, University of Minnesota
Terminated
Interventions: Procedure: Stem Cell Transplantation; Drug: Cyclophosphamide; Drug: Campath-1H; Drug: Busulfan
Sponsor: Masonic Cancer Center, University of Minnesota
Terminated
Condition: Osteopetrosis
Interventions: Procedure: Stem Cell or Umbilical Cord Blood Transplantation; Drug: Campath, Busulfan, Clofarabine; Procedure: Total Lymphoid Irradiation
Sponsor: Masonic Cancer Center, University of Minnesota
Terminated
Interventions: Procedure: Stem Cell or Umbilical Cord Blood Transplantation; Drug: Campath, Busulfan, Clofarabine; Procedure: Total Lymphoid Irradiation
Sponsor: Masonic Cancer Center, University of Minnesota
Terminated
Condition: Fanconi Anemia
Interventions: Biological: Anti-Thymocyte Globulin; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Hematopoietic Stem Cell Transplantation; Drug: Methylprednisolone; Drug: Filgrastim; Drug: Cyclosporine; Drug: Mycophenolate Mofetil
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2017
Interventions: Biological: Anti-Thymocyte Globulin; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Hematopoietic Stem Cell Transplantation; Drug: Methylprednisolone; Drug: Filgrastim; Drug: Cyclosporine; Drug: Mycophenolate Mofetil
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2017
Condition: Histiocytosis, Langerhans-cell
Interventions: Biological: alemtuzumab; Drug: fludarabine phosphate; Drug: melphalan; Procedure: stem cell transplantation
Sponsor: Masonic Cancer Center, University of Minnesota
Terminated
Interventions: Biological: alemtuzumab; Drug: fludarabine phosphate; Drug: melphalan; Procedure: stem cell transplantation
Sponsor: Masonic Cancer Center, University of Minnesota
Terminated
Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: busulfan; Drug: cyclophosphamide; Biological: Stem cell infusion; Radiation: Total body irradiation
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting
Interventions: Drug: busulfan; Drug: cyclophosphamide; Biological: Stem cell infusion; Radiation: Total body irradiation
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting
Condition: Leukemia
Interventions: Drug: cyclosporine; Drug: cytarabine; Drug: filgrastim; Drug: methotrexate; Drug: methylprednisolone; Drug: mitoxantrone hydrochloride; Procedure: allogeneic bone marrow transplantation; Procedure: umbilical cord blood transplantation; Drug: Cis-Retinoic acid
Sponsor: Masonic Cancer Center, University of Minnesota
Terminated
Interventions: Drug: cyclosporine; Drug: cytarabine; Drug: filgrastim; Drug: methotrexate; Drug: methylprednisolone; Drug: mitoxantrone hydrochloride; Procedure: allogeneic bone marrow transplantation; Procedure: umbilical cord blood transplantation; Drug: Cis-Retinoic acid
Sponsor: Masonic Cancer Center, University of Minnesota
Terminated
Conditions: Leukemia; Lymphoma; Multiple Myeloma; Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: umbilical cord blood transplantation; Drug: Allopurinol; Drug: fludarabine phosphate; Drug: Cyclophosphamide; Radiation: Total body irradiation; Biological: Treg infusion; Drug: Sirolimus
Sponsor: Masonic Cancer Center, University of Minnesota
Completed
Interventions: Biological: umbilical cord blood transplantation; Drug: Allopurinol; Drug: fludarabine phosphate; Drug: Cyclophosphamide; Radiation: Total body irradiation; Biological: Treg infusion; Drug: Sirolimus
Sponsor: Masonic Cancer Center, University of Minnesota
Completed
Conditions: Myelodysplastic Syndrome (MDS); Severe Aplastic Anemia (SAA)
Interventions: Other: Umbilical Cord Blood; Other: Haploidentical Stem Cells; Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 6, 2016
Interventions: Other: Umbilical Cord Blood; Other: Haploidentical Stem Cells; Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 6, 2016
